Experienced in Arthrogryposis Multiplex Congenita

Dr. Edward C. Smith

Pediatrics
2100 Erwin Rd, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Arthrogryposis Multiplex Congenita
2100 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Edward Smith is a Pediatrics provider in Durham, North Carolina. Dr. Smith is rated as an Experienced provider by MediFind in the treatment of Arthrogryposis Multiplex Congenita. His top areas of expertise are Pompe Disease, Muscle Atrophy, Hereditary Ataxia, and Delayed Growth. Dr. Smith is currently accepting new patients.

His clinical research consists of co-authoring 50 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Arthrogryposis Multiplex Congenita.

Specialties
Pediatrics
Licenses
Pediatrics in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS

Locations

2100 Erwin Rd, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Enrollment Status: Recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Other
An Open-Label, Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy Who Have Completed the Long-Term Extension (VBP15-LTE) or VBP15-004 or VBP15-006 Studies
An Open-Label, Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy Who Have Completed the Long-Term Extension (VBP15-LTE) or VBP15-004 or VBP15-006 Studies
Enrollment Status: Available
Publish Date: September 30, 2025
Intervention Type: Drug
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Genetic
Study Phase: Phase 3
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Drug
Study Drug: PEG-Zilarginase
Study Phase: Phase 3
A Phase 1 Study of the Safety of AAV2/8-LSPhGAA (ACTUS-101) in Late-onset Pompe Disease
A Phase 1 Study of the Safety of AAV2/8-LSPhGAA (ACTUS-101) in Late-onset Pompe Disease
Enrollment Status: Active_not_recruiting
Publish Date: June 28, 2023
Intervention Type: Biological
Study Drug: AAV2/8LSPhGAA
Study Phase: Phase 1/Phase 2
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: March 09, 2023
Intervention Type: Drug, Other
Study Drugs: Vamorolone, Prednisone
Study Phase: Phase 2
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: July 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: January 02, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

50 Total Publications

Reductions in functional muscle mass and ability to ambulate in Duchenne muscular dystrophy from ages 4 to 24 years.
Reductions in functional muscle mass and ability to ambulate in Duchenne muscular dystrophy from ages 4 to 24 years.
Journal: The Journal of physiology
Published: June 06, 2024
Similar Doctors
Distinguished in Arthrogryposis Multiplex Congenita
Dr. Arthur S. Aylsworth
Pediatrics
Distinguished in Arthrogryposis Multiplex Congenita
Dr. Arthur S. Aylsworth
Pediatrics
101 Manning Dr, 
Chapel Hill, NC 
 (9.8 miles away)
919-966-4131
Languages Spoken:
English

Arthur Aylsworth is a Pediatrics provider in Chapel Hill, North Carolina. Dr. Aylsworth is rated as an Advanced provider by MediFind in the treatment of Arthrogryposis Multiplex Congenita. His top areas of expertise are Arthrogryposis Multiplex Congenita, Hypochondroplasia, Micrognathia, and Early Infantile Epileptic Encephalopathy.

Vandana Shashi
Experienced in Arthrogryposis Multiplex Congenita
Dr. Vandana Shashi
Medical Genetics | Pediatrics
Experienced in Arthrogryposis Multiplex Congenita
Dr. Vandana Shashi
Medical Genetics | Pediatrics

Lenox Baker Children's Hospital

3000 Erwin Rd, 
Durham, NC 
 (1.0 miles away)
855-855-6484
Experience:
39+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

I am a clinical geneticist and a pediatrician with a deep interest in undiagnosed and rare genetic disorders. I provide medical care for children and adults with chromosome 22q11.2 deletion syndrome and diagnostic evaluation for patients with symptoms and signs of genetic disorders, when evaluations have not provided a specific diagnosis. Dr. Shashi is rated as a Distinguished provider by MediFind in the treatment of Arthrogryposis Multiplex Congenita. Her top areas of expertise are DiGeorge Syndrome, Hypotonia, Immune Defect due to Absence of Thymus, and Micrognathia.

Experienced in Arthrogryposis Multiplex Congenita
Dr. Chad Haldeman
Medical Genetics | Pediatrics
Experienced in Arthrogryposis Multiplex Congenita
Dr. Chad Haldeman
Medical Genetics | Pediatrics

The Moses H Cone Memorial Hospital Operating Corporation

1200 N Elm St, 
Greensboro, NC 
 (48.1 miles away)
336-574-7771
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chad Haldeman is a Medical Genetics specialist and a Pediatrics provider in Greensboro, North Carolina. Dr. Haldeman is rated as an Advanced provider by MediFind in the treatment of Arthrogryposis Multiplex Congenita. His top areas of expertise are Fabry Disease, Multiple Sulfatase Deficiency, Megalencephalic Leukoencephalopathy with Subcortical Cysts, and Danon Disease.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Smith's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile